Primaquine radical cure of Plasmodium vivax malaria: a risk-benefit analysis

间日疟造成严重的发病率，每年有1亿多个临床病例，并可导致复发性疾病和慢性贫血。间日疟原虫的唯一根治方法是使用伯氨喹，这可能导致某些患者出现严重的溶血。我们的研究旨在确定伯氨喹治疗间日疟的风险和益处，使用的数据来自已发表的临床试验的荟萃分析和大型多中心试验的个体患者结果。

Vivax malaria causes significant morbidity with over 100 million clinical cases each year and can cause a relapsing illness and chronic anaemia. The only available radical cure of P. vivax requires administration of primaquine, which can cause severe haemolysis in some patients. Our research aims to determine the risks and benefits of giving primaquine to cure vivax malaria using data from meta-analyses of published clinical trials and individual patient results from large multicentre trials.